It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are t ...

Baxter International Inc. (BAX) recently received the FDA’s approval for an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates. Clinolipid, which provides calories and essential fatty acids for parenteral nutrition, is currently available to order in the United States.Clinolipid has been available in the United States for adults since 2019 and is now available for use in all ages.The latest regulatory clearance is expected to ...

Baxter International (BAX) reported $3.59 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 1.6%. EPS of $0.65 for the same period compares to $0.59 a year ago.The reported revenue represents a surprise of +1.20% over the Zacks Consensus Estimate of $3.55 billion. With the consensus EPS estimate being $0.61, the EPS surprise was +6.56%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

FI RS T-Q UA RT ER 2024 EA RNI NGS Baxter International Inc. May 2, 2024 1 FORWA R D- LOOKING STAT EM ENT S ...

财务数据和关键指标变化 - 第一季度销售额为36亿美元,同比增长2%,超出公司此前预期的约1%增长 [10][11] - 调整后每股收益为0.65美元,同比增长33%,超出公司此前预期的0.59-0.62美元 [11][37] - 毛利率为42.5%,同比增加170个基点,超出预期 [49][50] - 营业利润率为14.3%,同比增加180个基点 [53] 各条业务线数据和关键指标变化 医疗产品与治疗(MPT) - 第一季度销售额增长6%,受益于定价和销量增长 [15] - 输液治疗与技术部门销售额增长6%,受益于国际市场和美国静脉输液业务的强劲需求 [38] - 先进外科销售额增长8%,超出预期,主要得益于国际市场的强劲增长 [39] 医疗系统与技术(HST) - 第一季度销售额下降9%,受到多方面因素影响,包括产品安装时间安排、资本订单时间安排以及某些运营挑战 [40][41][42] - 护理与连通性解决方案部门销售额下降7% [40] - 前线护理部门销售额下降12%,受到上年同期库存消化的不利影响以及初级护理市场疲软 [43] 制药 - 第一季度销售额增长11%,受益于美国新产品发布和海外药品复合服务需求增加 [45] 肾脏护理 - 第一季度销售额增长4%,受益于定价和急性治疗业务的强劲需求,但受到某些产品和市场退出以及中国政府采购计划影响 [46][47] 各个市场数据和关键指标变化 - 公司在美国、欧洲、拉丁美洲等市场表现良好,但在中国市场受到政府采购计划和患者人数下降的影响 [46] 公司战略和发展方向及行业竞争 - 公司正在推进肾脏护理业务的分拆,可能采取出售给私募股权投资者的方式 [30] - 公司在医疗产品与治疗(MPT)业务中推出了新的Novum IQ输液泵,获得FDA批准,预计将在下半年为公司带来显著贡献 [16][19] - 公司在制药业务中推出了5款新的注射剂产品,并持续关注提高利润率 [21][145] - 公司正在采取措施改善医疗系统与技术(HST)业务的运营和商业执行力 [28][29] 管理层对经营环境和未来前景的评论 - 公司受益于其专注于基本医疗需求的业务模式和多元化产品组合 [14] - 公司新的运营模式提高了全球可见性、问责制和职能垂直化,推动了业绩改善 [12][13] - 公司看好未来发展前景,将继续保持转型的步伐和强度,确保各业务部门做好准备 [31][32][33] 问答环节重要的提问和回答 问题1 **Vijay Kumar提问** 询问HST业务何时能够恢复正常增长轨道 [69][70][71] **Joe Almeida回答** 公司有信心HST业务在下半年会有显著改善,已采取具体措施来解决运营和商业执行方面的挑战 [72][73][74] 问题2 **Pito Chickering提问** 询问HST业务第一季度表现疲弱的具体原因以及下半年改善的原因 [83][84][85][86][87][88][89][90][91][92][93][94][95] **Joe Almeida和Joel Grade回答** 解释了HST业务在第一季度存在的运营和商业执行方面的问题,以及公司采取的具体改善措施,预计下半年会有显著改善 [85][86][87][88][89][90][91][92][93][94][95] 问题3 **Larry Biegelsen提问** 询问公司对肾脏护理业务分拆的考虑和决策时间 [113][114] **Joe Almeida回答** 公司正在考虑分拆或出售肾脏护理业务,将在2024年下半年做出决定,目标是最大化股东价值 [114]

Baxter International (BAX) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.56%. A quarter ago, it was expected that this drug and medical device maker would post earnings of $0.86 per share when it actually produced earnings of $0.88, delivering a surprise of 2.33%.Over the last fou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2024 RESULTS • First-quarter sales from continuing operations of $3.59 billion increased 2% on a reported basis and 3% on a constant currency basis, exceeding the company’s previously issued guidance1 • First-quarter U.S. GAAP2 diluted earnings per share (EPS) from continuing operations were $0.07 and adjusted diluted EPS from continuing operations were $0.65, exceeding the company’s previously issued guidance • Baxter now expects full-year 202 ...

Analysts on Wall Street project that Baxter International (BAX) will announce quarterly earnings of $0.61 per share in its forthcoming report, representing an increase of 3.4% year over year. Revenues are projected to reach $3.55 billion, declining 2.7% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a ...

Baxter International, Inc.新产品发布 - Baxter International, Inc.最近在美国推出了五种注射产品，扩大了其制药产品组合[1] - 这些新产品提供了现成的配方，满足了关键治疗领域患者的需求，并为医疗专业人员提供了额外的便利[2] Baxter International, Inc.股价表现 - Baxter的股价在过去六个月中上涨了32.3%，表现优于行业的21.7%和标普500指数的19.1%[3]